Aastrom Biosciences Inc Share Price Nasdaq
Equities
US00253U3059
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
05-08 | Vericel Q1 Loss Narrows, Revenue Increases; 2024 Outlook Lifted -- Shares Rise Pre-Bell | MT |
05-08 | Earnings Flash (VCEL) VERICEL CORPORATION Posts Q1 Revenue $51.3M, vs. Street Est of $49.1M | MT |
Sales 2024 * | 240M 19.18B | Sales 2025 * | 299M 23.92B | Capitalization | 2.34B 187B |
---|---|---|---|---|---|
Net income 2024 * | 5M 399M | Net income 2025 * | 24M 1.92B | EV / Sales 2024 * | 9.73 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.81 x |
P/E ratio 2024 * |
454
x | P/E ratio 2025 * |
102
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.07% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 28/02/13 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 24/01/21 |
Michael Halpin
COO | Chief Operating Officer | 62 | 09/04/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 05/01/15 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 05/01/15 |
Robert Zerbe
CHM | Chairman | 73 | 15/01/06 |
1st Jan change | Capi. | |
---|---|---|
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |